Company name:

Eagle Pharmaceuticals Inc

  • IPO SHARE PRICE:
    $15.00
  • IPO DATE:
    February 12, 2014
  • TICKER:
    EGRX
  • MAIN STOCK EXCHANGE:
    NASDAQ
  • CURRENT HQ LOCATION:
    50 Tice Boulevard Suite 315 Woodcliff Lake NJ 07677
  • FISCAL YEAR END:
    December 31
  • INCORPORATION JURISDICTION:
    DE
  • ORGANIZED AS THE FOLLOWING LEGAL TYPE:
    Corporation
  • Investor Relations Webpage:
    Coming soon!
  • TAX RATE:
    USA federal corporate nominal income tax rate is 21%

Short Description

Eagle Pharmaceuticals Inc

We are working hard and as soon as possible to provide company description soon. Feel free to reach out to request it sooner: improve@real-clear-investing.com

Income Statement

Quarterly Annual
(USD in thousand)
Selected Year:
31-Dec
2020
Revenue
Gross receipts in the form of cash (great!) and promises to pay (Account Receivables - not so great as some of them will never be collected but reality of business!) from all its customers
100%
58.8% —

Royalty revenue

38.5% —

Product revenue

2.7% —

License and other revenue
Selected Year:
Last Twelve Months LTM
Last Quarter Annualized LQA
Product revenue
45,679
45,679
 45,327 70,385 73,989 72,323 72,323 91,744
Royalty revenue
$45,679
$45,679
 153,880 142,927 112,903 110,479 110,479 107,920
License and other revenue
$45,679
$45,679
 37,500 - 9,000 5,000 5,000 -
Total Revenue
$45,679
$45,679
 $236,707 $213,312 $195,892 $187,802 $187,802 $199,664
Selected Year:
31-Dec
2020
Operating expenses
Cost (labor, materials, depreciation, overhead, etc) for delivering service or manufacturing a product that business sells
82.5%
41.9% —

Selling general and administrative

17.9% —

Cost of product sales

16.4% —

Research and development

6.3% —

Cost of royalty revenue

0.0% —

Restructuring

0.0% —

Asset impairment

0.0% —

Change in fair value of contingent consideration
Selected Year:
Last Twelve Months LTM
Last Quarter Annualized LQA
Cost of royalty revenue
45,679
45,679
 23,472 19,542 13,006 11,818 11,818 10,792
Cost of product sales
45,679
45,679
 33,714 42,374 47,891 33,647 33,647 39,372
Research and development
45,679
45,679
 32,607 44,419 36,810 30,785 30,785 37,580
Selling general and administrative
45,679
45,679
 71,416 60,509 76,370 78,598 78,598 72,748
Litigation settlement
45,679
45,679
 1,650 - - - - -
Gain or loss on sale of assets
45,679
45,679
 - - - - - -
Asset impairment
45,679
45,679
 7,235 2,704 - - - -
Restructuring
-
45,679
 - 7,911 - - - -
Change in fair value of contingent consideration
45,679
45,679
 (7,377) (763) - - - -
Total operating expenses
45,679
45,679
 $162,717 $176,696 $174,077 $154,848 $154,848 $160,492
Selected Year:
31-Dec
2020
Operating Income
Income after excluding Operating Expenses from Total Revenue
17.5%
17.5% —

Operating Income

Key metric that shows earnings potential of the company's business model
Selected Year:
Last Twelve Months LTM
Last Quarter Annualized LQA
Operating income
$45,679
$45,679
 $73,990 $36,616 $21,815 $32,954 $32,954 $39,172
Selected Year:
31-Dec
2020
Non-operating expenses
Cost usually unrelated to delivering service or manufacturing a product that business sells
4.4%
4.4% —

Other expense or income
Selected Year:
Last Twelve Months LTM
Last Quarter Annualized LQA
Other expense or income
-
-
 - - 700 (8,262) (8,262) -
Other income
-
-
 - - 700 - - -
Total non-operating income (expense)
45,679
45,679
 - - 700 (8,262) (8,262) -
Selected Year:
31-Dec
2020
Earnings before Interest and Taxes (EBIT)
Income after excluding Operating and Non-operating Expenses from Total Revenue
13.1%
13.1% —

EBIT

Another income metric but unlike Operating Income it is closer to the ultimate income metric - Net Income by removing expenses that are not related to earning Revenue as they are supposed to be accidental and transitory
Selected Year:
Last Twelve Months LTM
Last Quarter Annualized LQA
EBIT
$45,679
$45,679
 $73,990 $36,616 $22,515 $24,692 $24,692 $39,172
Selected Year:
31-Dec
2020
Interest Expense and Income, Taxes
Expenses driven mostly by company management's choices, nature of business (capital intensive vs not) about financing (debt vs equity) and legal structure
6.8%
0.3% —

Interest income

1.4% —

Interest expense

5.7% —

Income tax expense or benefit
Selected Year:
Last Twelve Months LTM
Last Quarter Annualized LQA
Interest expense
45,679
45,679
 (1,136) (2,736) (2,686) (2,577) (2,577) (1,652)
Interest income
45,679
45,679
 91 158 2,169 562 562 80
Total other expense or income
45,679
45,679
 (1,045) (2,578) 183 (10,277) (10,277) 6,376
Income before income taxes
45,679
45,679
 72,945 34,038 21,998 22,677 22,677 45,548
Income tax expense or benefit
45,679
45,679
 21,002 2,135 7,685 10,688 10,688 72,184
Selected Year:
31-Dec
2020
Net income (loss)
Ultimate measure of Income - Net result after excluding all expenses from Total Revenue
6.4%
6.4% —

Net income (loss)

It is a residue that is left from Total Revenue after paying all kind of expenses and belongs to all equity holders in the company. Some of these shareholders such Non-controlling interest or Preferred equity gets their share before Common shareholders
Selected Year:
Last Twelve Months LTM
Last Quarter Annualized LQA
Net income (loss)
$45,679
$45,679
 $51,943 $31,903 $14,313 $11,989 $11,989 $32,228

Basic Shares Outstanding
Basic shares outstanding as of certain dates reported by Company on its annual and quarterly filings, these numbers are NOT used calculation of basic EPS. They help to see share issuance by company in perspective
Common
-
-
 14,862,015 13,924,296 13,679,350 13,217,284 13,217,284 13,217,284
Selected Year:
31-Dec
2020
EPS
Net Income / Shares Outstanding = EPS before dilution or Basic EPS; Net Income/ ( Shares Outstanding + potentially available shares from conversion of various option instruments)
Selected Year:
Last Twelve Months LTM
Last Quarter Annualized LQA
Net Income per basic share
$45,678,795.00
$45,678,795.00
 $3.44 $2.16 $1.04 $0.89 $0.89 $2.40
Net Income per diluted share
$45,678,795.00
$45,678,795.00
 $3.27 $2.09 $1.01 $0.87 $0.87 $2.36